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Biomarker
SurveillanceLooking for novel serummarkers for early detection of hepatocellu-
lar carcinoma (HCC) has been a hot area of research for more than
20 years. Notwithstanding the intensive research efforts, there have
been scanty serum markers with optimal performance for generalized
clinical use. This is partly because HCC typically arises from the back-
ground of diseased liver with long standing cirrhotic and hepatitic
changes, whereas few markers are speciﬁcally expressed in tumors
without co-expression in non-tumorous tissue. HCC is also known to
be a highly heterogeneous cancer, with different etiological, geographi-
cal and genetic compositions. As a result, it is difﬁcult to identify a single
marker suitable for all HCC patients. Taking alpha-fetoprotein (AFP) as
an example, the sensitivity is approximately 70% in diagnosis of HCC
but it becomes lower in the setting of surveillance for small sized
tumor (Chan et al., 2014). In addition, AFP is limited by the false-
positivity in patients with active hepatitis. As compared to hepatitis
B virus (HBV) infection, this problem appears to be worse for hepatitis
C virus (HCV) infection, which is characterized by variable degree of
chronic active hepatitis. Although recent data indicate that the speciﬁc-
ity of AFP could improve after treatment with effective anti-viral
therapy which diminishes the hepatitis activity (Wong et al., 2014;
Oze et al., 2014), it remains controversial whether serum AFP should
be recommended for surveillance of HCC. To overcome above weak-
nesses, various serum markers for HCC have been tested with notableDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.04.007.
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(PIVKA-II) and Lens culinaris agglutinin-reactive AFP (AFP-L3). These
markers are associated with higher speciﬁcity in diagnosis of HCC, but
at a cost of lower sensitivity (Sterling et al., 2009). As a result, none of
them are considered very useful markers for surveillance of HCC.
In this issue of EBioMedicine, Ezzikouri et al. reported on the use of a
novel serum marker, 3β-hydroxysterol Δ24-reductase auto-antibody
(DHCR24 Ab), as a surrogate marker to indicate progression from
chronic hepatitis C to HCC (Ezzikouri et al., 2015). By evaluating
serum levels of the antibody in patients with different stages of disease,
itwas found that the concentration of DHCR24Ab in theHCC cohortwas
higher than cirrhotic patients, while the levels in cirrhotic patients were
higher than thehepatitis cohort andhealthy subjects, respectively. In di-
agnosing HCC, the performance of serum DHCR24 Ab was better than
AFP (cutoff at 20 ng/ml) and PIVKA-II (cutoff at 40m IU/ml) with higher
sensitivity, speciﬁcity and area-under-curve (AUC) at the cutoff of
11.5 μg/ml. Further, DHCR24 Ab was elevated in more than 70% of pa-
tients who did not have elevation of AFP or PIVKA-II, and the combina-
tion of serumDHCR24 Abwith AFP and PIVKA-II had good sensitivity of
higher than 87% in diagnosis of HCC. All of these phenomena were only
observed in theHCVpopulation but not in theHBVpatients. The authors
conclude that serum DHRC24 Ab is a potential marker for HCV-related
liver disease and may facilitate the diagnosis of HCC.
The authors have to be congratulated for conducting such a large-
scaled clinical study with sample size of more than 600 patients. This
robust sample size has enabled statistical analysis of the diagnostic
and prognostic performance of the novel marker in different stages
and etiology groups of patients. We concur that the DHCR24 Ab is wor-
thy of further investigations for potential clinical use in prognostication
of severity and surveillance of HCC in patients with HCV infection. There
are several areas in which the marker can be developed to match the
need in real-world setting. First, a number of predictive models have
already been developed to gauge the risk of progression of HCV infec-
tion, by incorporating multiple clinical factors, including AST/ALT ratio,
bilirubin and albumin levels (Bonis et al., 1999; Ghany et al., 2010). It
remains unclear whether serum DHCR24 Ab provides independent
prognostication to those predictive models or clinical factors. Second,
clinicians nowadays rely on abdominal ultrasonography for surveillance
of HCC. Recent study suggested that the combination of serum marker
AFP and abdominal ultrasonography could improve the effectiveness
of HCC surveillance (Chang et al., 2015). Therefore, it is crucial tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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raphy in the surveillance of HCC. Third, only the serum sample collected
at one single timepoint has been studied based on the belief that the an-
tibody level is reﬂective of quantity of DHCR24 protein. Nevertheless,
the production of antibody is prone to be inﬂuenced by other factors
such as host's immunity and the presence of concomitant active infec-
tion. It is unclear whether any the antibody level ﬂuctuates along the
disease course of HCV infection, particularly after antiviral treatment.
To address this question, future investigations should involve study on
quantiﬁcation of DHCR24 Ab in serial serum samples in the patient co-
hort. Fourth, DHCR24 participates in cholesterol synthesis with its
blood level in close correlation with body weight, fast glucose level
and HbA1c (Berisha et al., 2011). Hence, the potential applicability of
serum DHCR24 Ab in prognostication of patients with non-alcoholic
fatty liver disease, which is the commonest metabolic liver disease
worldwide, should be explored.
In summary, the current study by Ezzikouri et al. has undoubtedly
provided researchers a novel marker to work on, in particular for sur-
veillance of HCC in HCV population. However, previous experiences of
developing tumor markers have already taught us that HCC and HCV
are both complex diseases. A lot more works are required to determine
whether DHCR24 Ab represents a promising hope for patients.
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